250 related articles for article (PubMed ID: 1717669)
1. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
2. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
[TBL] [Abstract][Full Text] [Related]
3. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
5. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
6. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
7. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
8. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
9. 186Re-etidronate in breast cancer patients with metastatic bone pain.
Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
[TBL] [Abstract][Full Text] [Related]
10. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Klutmann S; Bohuslavizki KH
MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases.
Maxon HR; Thomas SR; Hertzberg VS; Schroder LE; Englaro EE; Samaratunga R; Scher HI; Moulton JS; Deutsch EA; Deutsch KF
Semin Nucl Med; 1992 Jan; 22(1):33-40. PubMed ID: 1375400
[TBL] [Abstract][Full Text] [Related]
12. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Schoeneich G; Palmedo H; Dierke-Dzierzon C; Müller SC; Biersack HJ
Scand J Urol Nephrol; 1997 Oct; 31(5):445-8. PubMed ID: 9406304
[TBL] [Abstract][Full Text] [Related]
13. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.
Limouris GS; Shukla SK; Condi-Paphiti A; Gennatas C; Kouvaris I; Vitoratos N; Manetou A; Dardoufas C; Rigas V; Vlahos L
Anticancer Res; 1997; 17(3B):1767-72. PubMed ID: 9179232
[TBL] [Abstract][Full Text] [Related]
14. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
15. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
16. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Liepe K; Kropp J; Hliscs R; Franke WG
Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
[TBL] [Abstract][Full Text] [Related]
17. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
